Opthea Limited is an Australian biotechnology company focused on the development and commercialization of innovative therapeutic solutions for eye diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema. Founded in 2009, its main research focus is on developing drugs targeting the regulation of angiogenesis (the formation of new blood vessels) in the retina. Opthea is dedicated to advanced molecular therapies that offer new possibilities for treating eye diseases and improving visual function in patients. The company has several products in clinical trial phases and aims to bring them to the global market.
Feed
There are no posts to show right now.
Używamy ciasteczek, aby ulepszyć Twoje doświadczenie na naszej stronie.
